<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90643">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01805453</url>
  </required_header>
  <id_info>
    <org_study_id>P120105</org_study_id>
    <secondary_id>2012-004536-34</secondary_id>
    <nct_id>NCT01805453</nct_id>
  </id_info>
  <brief_title>Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma</brief_title>
  <acronym>ASTER</acronym>
  <official_title>Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma- A Randomized Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ANOCEF (french association of neuro-oncologists)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <authority>France: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy of an Angiotensin-II inhibitor (Losartan) to reduce peritumoral edema
      in newly diagnosed glioblastoma patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicentre, randomized (1:1), double blinded trial:- Arm A: Standard of care (Radiotherapy
      with concomitant temozolomide followed by monthly cures of temozolomide ) + Losartan
      50mg*2/day until the halting for any reason - Arm B: Standard of care (Radiotherapy  with
      concomitant temozolomide followed by monthly cures of temozolomide + Placebo 2/day until the
      halting for any reason.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Steroid dosage required to control brain edema on the last day of radiotherapy in each arm</measure>
    <time_frame>Up to Day 42+ 1 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Steroids dosage 1 month after the end of RT</measure>
    <time_frame>Day 42+ 1 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of cerebral edema on MRI</measure>
    <time_frame>Day -28 at -13, Day 42, Day 42+1 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance (NCI-CTCAE v3.0)</measure>
    <time_frame>up to day42 +1 month + 7 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To be reported according to NCI/CTC version 3.0 (adverse events)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Day -10 at -7, Day0, 42, Day 42+1month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1C</measure>
    <time_frame>Day -10 at -7, D42, Day 42+1month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glycemia</measure>
    <time_frame>Day -10 at -7, Day14, 28, 42, Day 42+1month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body weight</measure>
    <time_frame>Day -10 at -7, Day42, Day 42+1month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side-effects of steroids</measure>
    <time_frame>up to day42 +1 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Executive functions ( &quot; Moca test &quot;)</measure>
    <time_frame>Day-10 at -7, Day 42, Day 42+1 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (EORTC)</measure>
    <time_frame>Day-10 at -7, Day 42, Day 42+1 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Newly-diagnosed Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Arm A: Losartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm A: Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide ) + Losartan 50mg*2/day until the halting for any reason</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Arm B: Standard of care (Radiotherapy  with concomitant temozolomide followed by monthly cures of temozolomide + Placebo 2/day until the halting for any reason</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide ) + Losartan or placebo (Arm A or B) 50mg*2/day until the halting for any reason</description>
    <arm_group_label>Arm A: Losartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Standard of care (Radiotherapy  with concomitant temozolomide followed by monthly cures of temozolomide + Placebo 2/day until the halting for any reason</description>
    <arm_group_label>Arm B: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older

          -  Histologically confirmed glioblastoma (Grade 4 WHO)

          -  patients eligible for radiotherapy and concomitant Temozolomide

          -  KPS ≥ 50%

          -  Adequate hematologic, liver and renal functions

        Exclusion Criteria:

          -  Patients unable to undergo an MRI with contrast

          -  Patients without any residual tumor left on the screening MRI of both flair and
             contrast-enhanced lesions complete surgical resection)

          -  Any prior treatment of glioblastoma including any local therapy (immunotherapy,
             Gliadel wafers, …..) during or after surgical resection

          -  Any on-going treatment for high blood pressure at time of inclusion, whatever the
             therapeutic class of drugs

          -  Systolic blood pressure &lt;110 mmHg.

          -  relative or definite contra-indication to Losartan:

          -  Pregnant or breast feeding women; Women with an intact uterus (unless amenorrhoeic
             for the last 24 months) not using effective means of contraception

          -  Non-affiliation to the &quot;sécurité sociale&quot;
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoine CARPENTIER, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antoine CARPENTIER, MD, PhD</last_name>
    <phone>+33 1 48 95 54 91</phone>
    <email>antoine.carpentier@avc.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Neurology Department - Avicenne Hospital</name>
      <address>
        <city>Bobigny</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine CARPENTIER, MD, PhD</last_name>
      <phone>+33 1 48 95 54 91</phone>
      <email>antoine.carpentier@avc.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Antoine CARPENTIER, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 30, 2014</lastchanged_date>
  <firstreceived_date>February 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioblastoma</keyword>
  <keyword>Angiotensin-II inhibitors</keyword>
  <keyword>Losartan</keyword>
  <keyword>steroids</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Edema</keyword>
  <keyword>Randomized trial</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angiotensin II</mesh_term>
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
